$GNSZ News: GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting

SAN ANTONIO, - (http://www.financialnewsmedia.com News Alert) - GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5th Asia-Pacific Primary Liver Cancer Expert Meeting Saturday, July 12th, in Taipei, Taiwan. Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months



Dr. Mahalingam, an oncologist at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio, presented interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of, sorafenib. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study.



\"The efficacy and safety analyses on patients enrolled to date on this study continue to demonstrate that G-202 holds promise for patients with advanced HCC, with half the patients showing disease stability at 4 months and the majority of patients tolerating G-202 with minimal toxicities,\" stated Dr. Mahalingam.



\"DCE-MRI is a sophisticated imaging technique that allows us to assess effects of G-202 on tumor blood flow characteristics,\" said Dr. Craig Dionne, GenSpera CEO. \"The DCE-MRI data in the single patient evaluated to date provide strong evidence that G-202 is significantly decreasing tumor blood flow in a fashion for which it was designed. We will extend this diagnostic procedure in future patients to confirm this important proof of concept observation.\" Dr. Dionne continued, \"These positive results enable management to remain optimistic about our ambitious G-202 clinical development program which is expanding into glioblastoma, prostate cancer and renal cell carcinoma trials. Although still in early stages, we believe this clinical strategy will continue to build significant value in G-202 and in the company. We are particularly excited by...